This website uses cookies. By using this website, you agree to our Cookie Policy.
October 12, 2020
Cadwalader Intellectual Property Group Chair and Partner Dorothy Auth shares her insights on the timing of Allele Biotech’s patent infringement lawsuits against Pfizer and Regeneron in connection with their use of Allele’s patented molecules to develop COVID-19 treatments. Dorothy also comments on the case’s specific issue of how research tools are used in developing pharmaceutical products.
